Search Results

Medtronic's In.Pact Admiral DCB Compared to PTA in IN.PACT SFA Trial

September 19, 2016—Prakash Krishnan, MD, presented results from the IN.PACT SFA trial during the first Late-Breaking Trials session at VIVA 16, the 14th annual Vascular InterVentional Advances meeting, which is sponsored by VIVA Physicians, Inc. and held September 18–22, 2016 at the Wynn Las Vegas in Las Vegas, Nevada.

Two-Year Results Presented for Spectranetics' Stellarex in the Direct DCB Cohort of ILLUMENATE FIH Trial

November 2, 2015—Prakash Krishnan, MD, presented 2-year data from the ILLUMENATE first-in-human study, which was designed to assess the safety and effectiveness of the Stellarex drug-coated balloon (DCB, Spectranetics Corporation) to inhibit restenosis in the femoropopliteal artery in the treatment of peripheral artery disease.

Second Interim Analysis of ILLUMENATE Global Study Presented for Spectranetics' Stellarex DCB

June 1, 2016—Spectranetics Corporation announced that an interim analysis of 12-month data from the ILLUMENATE Global Study was presented by Prakash Krishnan, MD, at the New Cardiovascular Horizons annual conference held June 1–3 in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the company’s Stellarex drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.

Algorithm Developed to Determine Need for Embolic Protection During Femoropopliteal Atherectomy

February 22, 2017—A study that sought to develop an algorithm for the use of distal embolic protection during atherectomy for femoropopliteal lesions was published by Prakash Krishnan, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2017;10:403–410).

Medtronic’s In.Pact Admiral Evaluated in Pooled Analysis of DCB Effectiveness

November 9, 2021—A pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness in patients treated with Medtronic’s In.Pact Admiral DCB was presented by Prakash Krishnan, MD, in an Endovascular Featured Clinical Research session at TCT 2021 in Orlando, Florida.

ILLUMENATE Pivotal and Pharmacokinetic Studies Published for Spectranetics' Stellarex DCB

August 2, 2017—The 12-month outcomes from the randomized ILLUMENATE Pivotal and Pharmacokinetic (PK) studies of the Stellarex drug-coated balloon (DCB; Spectranetics Corporation) for the treatment of femoropopliteal disease were published online ahead of print by Prakash Krishnan, MD, et al in Circulation.

ILLUMENATE Pivotal Trial Results Presented for Spectranetics' Stellarex Drug-Coated Balloon

November 2, 2016—The Spectranetics Corporation announced that the final 12-month results of the ILLUMENATE pivotal trial for the company’s Stellarex drug-coated balloon (DCB) were presented by Sean P. Lyden, MD, at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC. Dr. Lyden and Prakash Krishnan, MD, serve as coprincipal investigators of ILLUMENATE. 

Terumo’s Cross-Seal Suture-Mediated Vascular Closure Device System Studied in IDE Trial

November 4, 2022—The objective of the prospective, multicenter, single-arm Cross-Seal investigational device exemption (IDE) trial was to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device (Terumo Interventional Systems) in obtaining hemostasis at the target limb access site after interventional procedures using 8- to 18-F procedural sheaths.

FDA Approves Spectranetics' Stellarex Drug-Coated Balloon

July 26, 2017—The Spectranetics Corporation announced receipt of US Food and Drug Administration premarket approval (PMA) of the Stellarex drug-coated balloon (DCB), which is designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).

New Data Presented for Medtronic's In.Pact Admiral Drug-Coated Balloon

September 19, 2016—Medtronic plc announced that 3-year results from the pivotal IN.PACT SFA Trial and 1-year, real-world results from the full clinical cohort of the IN.PACT Global Study were revealed in late-breaking clinical trial presentations at VIVA 16, the Vascular InterVentional Advances annual conference in Las Vegas, Nevada.

BD Begins Postmarket XTRACT Registry of Rotarex Catheter to Treat PAD

October 9, 2025—BD (Becton, Dickinson and Company) announced the enrollment of the first patient in the XTRACT registry, which is designed to assess the real-world performance of the company’s Rotarex catheter system in the treatment of peripheral artery disease (PAD) lesions.

BD Rotarex to Be Assessed in XTRACT Postmarket Registry

May 28, 2025—BD (Becton, Dickinson and Company) announced plans to initiate the XTRACT patient data registry for its Rotarex atherectomy system.